Astera Labs Beat and Raised Guidance, Analysts Cut Anyway

Astera Labs Beat and Raised Guidance, Analysts Cut Anyway

Published on Nov 9, 2026

Quick read

  • Q3 revenue of $584.9 million rose 154% from a year earlier and beat the $550.8 million consensus
  • Q4 revenue guided to $730 million to $750 million, with the midpoint about 13% above consensus
  • TD Cowen cut its target to $225 from $300, and RBC, Susquehanna and Needham also cut
  • Shares fell 4.4% Wednesday and 19.6% Thursday, then rose 6.3% Friday, ending the week down 18%
  • Stock rating of 76.7, ranked 46th of 817 in its sector, with a $325 consensus target

Astera Labs (ALAB) delivered the kind of quarter that usually sends a stock higher. Record revenue, a clear beat against expectations, and guidance for the next quarter far above what analysts had penciled in. The shares fell anyway, and the firms that cover the stock spent the next day cutting their price targets. The quarter was not the problem. The price was.

The quarter itself was strong

Astera Labs reported third-quarter results after the close on Tuesday, November 3. Revenue reached a record $584.9 million, up 154% from a year earlier and 49% from the prior quarter, against a consensus estimate of about $550.8 million. It also cleared the top of the company's own guidance, which had been $540 million to $560 million. Non-GAAP earnings were $1.32 a share against a $1.19 estimate, while GAAP earnings were $0.99 a share on net income of $182.9 million. Non-GAAP gross margin was 72.4% and the non-GAAP operating margin reached 44.7%, up from 39.1% in the prior quarter.

The growth came from Scorpio, the company's family of fabric switches. A fabric switch is the hardware that links many AI processors together so they can work as one system, moving data between chips at high speed instead of letting each chip wait on the others. The Scorpio X-Series, the 320-lane version built for the largest AI clusters, entered high-volume production during the quarter and became the company's largest product family by revenue, with annualized revenue now above $1 billion. Astera Labs also makes retimers, chips that clean up and boost electrical signals as data travels across a server board, and it sells into the PCIe and CXL standards, the shared languages that let processors, memory and accelerators talk to each other inside a server.

The guidance was stronger still

For the fourth quarter, management guided revenue to $730 million to $750 million. The midpoint of $740 million sits about 13% above the roughly $655.8 million consensus, and implies growth of about 27% from the third quarter. Fourth-quarter non-GAAP earnings guidance of $1.62 to $1.66 a share came in well above the roughly $1.42 consensus, with gross margin expected near 72%.

Nothing in the release pointed to a slowdown. The next product in the pipeline, Aries 7, only starts sampling with customers in the fourth quarter, so its revenue is still ahead. The quarter and the guide together describe a company selling more, faster, into the largest AI buildout in the industry's history.

Then the targets came down

The cuts arrived on Wednesday, the first trading day after the results, and they were broad. TD Cowen cut its price target to $225 from $300 and kept a Hold rating. Royal Bank of Canada cut its target to $400 from $500 while keeping an Outperform rating. Susquehanna cut to $258 from $310 with a Neutral rating. Needham cut to $300 from $425 while keeping a Buy rating. UBS and Evercore ISI also lowered their targets. The average target across the firms that revised fell to about $366 from about $415.

Firm Old target New target Rating
TD Cowen $300 $225 Hold
Royal Bank of Canada $500 $400 Outperform
Susquehanna $310 $258 Neutral
Needham $425 $300 Buy

Not every firm moved the same way. Morgan Stanley raised its target to $389, Northland Securities upgraded the shares to Outperform with a $315 target, and BMO Capital Markets started coverage with an Outperform rating and a $375 target. The disagreement is the story: the same quarter read as a reason to pay up by some firms and a reason to mark down by others.

The stated worry in the coverage was valuation. Astera Labs had run hard through the year, and even after the week's fall the shares still carried a premium multiple. The stock closed Friday at $190.71, up 6.26% on the day, with a market value of $33.09 billion, a trailing price-to-earnings ratio of 75.68, a forward ratio of 41.64 and a stock rating of 76.7. The rating sits 46th of 817 stocks in the sector, with fundamentals labeled Excellent, market sentiment Neutral and moat Narrow. Fourteen analysts cover the stock with a consensus Buy rating and a $325 target, which implies about 70% upside from Friday's close.

The market reaction, day by day

Wednesday brought the first verdict: the shares closed at $223.27, down 4.4% from Tuesday's close of $233.62, the day the target cuts landed. Thursday was far worse. The shares closed at $179.47, down 19.6% on the day, as the TD Cowen cut was cited as a trigger and the whole AI hardware sector sold off in the same session. Friday brought a partial recovery, up 6.3% to $190.71. Across the three sessions after the report, the stock lost about 18%.

That sequence is what makes the week strange. The beat was real, the guidance was real, and the cuts were real too. Analysts were not disputing the quarter. They were disputing what it is worth paying for, after a run that had already priced in a great deal of growth. A $740 million quarter on the horizon is a strong number. Whether it supports the multiple the shares carried into earnings week is the question the market spent three days answering, and the answer so far is no.

This article is for information purposes only and is not financial advice.

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.